Published in J Virol on April 03, 2013
Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. Hum Vaccin Immunother (2013) 0.86
Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases. Clin Exp Vaccine Res (2015) 0.83
The Immune Response in Measles: Virus Control, Clearance and Protective Immunity. Viruses (2016) 0.75
Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression. J Virol (2016) 0.75
The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell (1993) 7.71
Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol (1993) 7.27
SLAM (CDw150) is a cellular receptor for measles virus. Nature (2000) 6.07
Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet (2012) 5.55
Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med (2008) 4.95
Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med (2008) 4.68
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Measles antibody: reevaluation of protective titers. J Infect Dis (1990) 3.77
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology (2010) 3.51
Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog (2009) 3.35
Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol (2001) 3.27
Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature (2011) 2.94
Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog (2011) 2.74
Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr (1977) 2.66
The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin Exp Immunol (1981) 2.54
Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol (2004) 2.42
Measles. Lancet (2011) 2.37
Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A (1993) 2.35
DNA vaccines: progress and challenges. J Immunol (2005) 2.34
Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int J Epidemiol (2009) 2.28
Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol (2008) 2.23
Global measles elimination. Nat Rev Microbiol (2006) 2.21
The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today (2000) 2.03
Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev (2010) 1.99
IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol (2011) 1.95
The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis (2007) 1.89
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Recent advances in the IL-17 cytokine family. Curr Opin Immunol (2011) 1.86
Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA (1998) 1.83
Experimental measles. I. Pathogenesis in the normal and the immunized host. Virology (1997) 1.83
Plasma cell development and survival. Immunol Rev (2010) 1.74
Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol (2000) 1.72
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Th17 cytokines and the gut mucosal barrier. J Clin Immunol (2010) 1.64
Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum Gene Ther (1995) 1.49
Case-fatality rate during a measles outbreak in eastern Niger in 2003. Clin Infect Dis (2005) 1.45
A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med (2003) 1.39
Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. J Infect Dis (1992) 1.38
Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med (1999) 1.35
The immortality of humoral immunity. Immunol Rev (2010) 1.33
A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci U S A (2004) 1.31
Regulation of epithelial immunity by IL-17 family cytokines. Trends Immunol (2012) 1.29
Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis (1997) 1.29
Distinct kinetics for binding of the CD46 and SLAM receptors to overlapping sites in the measles virus hemagglutinin protein. J Biol Chem (2002) 1.28
Loss of IL-17-producing CD8 T cells during late chronic stage of pathogenic simian immunodeficiency virus infection. J Immunol (2010) 1.26
Developing DNA vaccines that call to dendritic cells. J Clin Invest (2004) 1.24
Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol (2002) 1.23
Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin (2007) 1.23
Efficiency of measles virus entry and dissemination through different receptors. J Virol (2002) 1.22
CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity (2002) 1.18
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine (2010) 1.17
Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A (2005) 1.16
Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine (2001) 1.14
Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis (2002) 1.14
Measles virus receptor SLAM (CD150). Virology (2002) 1.14
Measles virus, immune control, and persistence. FEMS Microbiol Rev (2012) 1.12
Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci U S A (2012) 1.08
The natural and the inducible: interleukin (IL)-17-producing γδ T cells. Trends Immunol (2012) 1.04
Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin (2006) 1.03
Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr Opin HIV AIDS (2011) 1.01
Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. J Immunol (2012) 1.00
A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol (2010) 0.99
Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology (2000) 0.99
Progress in global measles control and mortality reduction, 2000-2006. MMWR Morb Mortal Wkly Rep (2007) 0.99
IL-17 boosts proinflammatory outcome of antiviral response in human cells. J Immunol (2011) 0.98
Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. Clin Pharmacol Ther (2007) 0.94
Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv (2010) 0.94
Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine (2011) 0.93
Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. J Infect Dis (2007) 0.93
A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine (2012) 0.93
Diversity of IL-17-producing T lymphocytes. Cell Mol Life Sci (2012) 0.91
Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol (2003) 0.90
Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol (2008) 0.89
Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol (2012) 0.89
Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genet Vaccines Ther (2006) 0.86
Increased frequency of Th17 cells in the peripheral blood of children infected with enterovirus 71. J Med Virol (2012) 0.85
Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Hum Vaccin Immunother (2012) 0.82
Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine (2005) 0.81
Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine (2005) 0.80
Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine (2004) 0.80
Enhancing effect of vaxfectin on the ability of a Japanese encephalitis DNA vaccine to induce neutralizing antibody in mice. Viral Immunol (2003) 0.78
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2010) 9.18
Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2010) 6.93
Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke (2003) 4.13
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke (2008) 4.06
Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Stroke (2005) 3.74
Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med (2005) 3.38
Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection. J Virol (2002) 2.55
Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Circulation (2005) 2.38
Measles. Lancet (2011) 2.37
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis (2008) 2.27
Prevalence of asthma and asthma action plans in South Australia: population surveys from 1990 to 2001. Med J Aust (2003) 2.23
Global measles elimination. Nat Rev Microbiol (2006) 2.21
Trends in hospital admissions and mortality from asthma and chronic obstructive pulmonary disease in Australia, 1993-2003. Med J Aust (2007) 2.20
Remote evaluation of acute ischemic stroke: reliability of National Institutes of Health Stroke Scale via telestroke. Stroke (2003) 2.17
Adverse drug events and medication errors in Australia. Int J Qual Health Care (2003) 2.03
MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr Blood Cancer (2008) 2.01
How valid are self-reported height and weight? A comparison between CATI self-report and clinic measurements using a large cohort study. Aust N Z J Public Health (2006) 1.97
Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care (2013) 1.93
The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med (2002) 1.92
The North West Adelaide Health Study: detailed methods and baseline segmentation of a cohort for selected chronic diseases. Epidemiol Perspect Innov (2006) 1.91
The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis (2007) 1.89
Declining stroke rates in Californian children with sickle cell disease. Blood (2004) 1.83
Luciferase imaging of a neurotropic viral infection in intact animals. J Virol (2003) 1.83
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood (2009) 1.83
Sickle cell disease: the neurological complications. Ann Neurol (2002) 1.77
IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci U S A (2007) 1.77
Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer (2010) 1.75
Diastolic dysfunction is associated with myocardial viral load in simian immunodeficiency virus-infected macaques. AIDS (2012) 1.68
Platelet activation and platelet-monocyte aggregate formation contribute to decreased platelet count during acute simian immunodeficiency virus infection in pig-tailed macaques. J Infect Dis (2013) 1.57
Organized stroke care. Stroke (2006) 1.56
BAK alters neuronal excitability and can switch from anti- to pro-death function during postnatal development. Dev Cell (2003) 1.56
Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood (2013) 1.52
Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood (2006) 1.45
Pathophysiology and treatment of stroke in sickle-cell disease: present and future. Lancet Neurol (2006) 1.39
A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med (2003) 1.39
Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis (2007) 1.38
REACH: clinical feasibility of a rural telestroke network. Stroke (2005) 1.38
Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis (2010) 1.37
Suppression of human immunodeficiency virus replication during acute measles. J Infect Dis (2002) 1.31
Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke (2006) 1.31
Prevalence of hypertension by duration and age at exposure to the stroke belt. J Am Soc Hypertens (2010) 1.29
Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy. Clin Infect Dis (2008) 1.27
Gamma interferon-dependent, noncytolytic clearance of sindbis virus infection from neurons in vitro. J Virol (2005) 1.25
Class II fusion protein of alphaviruses drives membrane fusion through the same pathway as class I proteins. J Cell Biol (2005) 1.25
Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin (2007) 1.23
Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). J Pediatr Hematol Oncol (2002) 1.22
Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis (2007) 1.22
Application of beta regression to analyze ischemic stroke volume in NINDS rt-PA clinical trials. Neuroepidemiology (2011) 1.21
Synergistic roles of antibody and interferon in noncytolytic clearance of Sindbis virus from different regions of the central nervous system. J Virol (2007) 1.21
Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis (2008) 1.21
Do people with risky behaviours participate in biomedical cohort studies? BMC Public Health (2006) 1.20
Measles: immune suppression and immune responses. Int J Biochem Cell Biol (2004) 1.18
Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children. J Infect Dis (2002) 1.18
Telestroke: extending stroke expertise into underserved areas. Lancet Neurol (2006) 1.17
Teleneurology applications: Report of the Telemedicine Work Group of the American Academy of Neurology. Neurology (2013) 1.17
HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis (2009) 1.17
Glutamate receptor antagonists protect from virus-induced neural degeneration. Ann Neurol (2004) 1.16
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol (2003) 1.16
Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A (2005) 1.16
Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection. Proc Natl Acad Sci U S A (2008) 1.15
VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem (2007) 1.15
Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol (2003) 1.15
Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis (2002) 1.14
Genetic predictors for stroke in children with sickle cell anemia. Blood (2011) 1.12
Gene expression patterns in dendritic cells infected with measles virus compared with other pathogens. Proc Natl Acad Sci U S A (2006) 1.12
Risk of recurrent stroke, myocardial infarction, or death in hospitalized stroke patients. Neurology (2010) 1.12
Contribution of T cells to mortality in neurovirulent Sindbis virus encephalomyelitis. J Neuroimmunol (2002) 1.10
Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling. J Virol (2009) 1.09
A web-based telestroke system facilitates rapid treatment of acute ischemic stroke patients in rural emergency departments. J Emerg Med (2008) 1.09
Central obesity is associated with nonatopic but not atopic asthma in a representative population sample. J Allergy Clin Immunol (2006) 1.09
Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci U S A (2012) 1.08
Central nervous system correlates of behavioral deficits following simian immunodeficiency virus infection. J Neurovirol (2003) 1.08
Remote evaluation of acute ischemic stroke in rural community hospitals in Georgia. Stroke (2004) 1.08
Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis (2004) 1.07
Intraplaque hemorrhage in symptomatic intracranial atherosclerotic disease. J Neuroimaging (2011) 1.07
A single mutation in the E2 glycoprotein important for neurovirulence influences binding of sindbis virus to neuroblastoma cells. J Virol (2002) 1.07
Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. Blood (2003) 1.06
The nsP3 macro domain is important for Sindbis virus replication in neurons and neurovirulence in mice. Virology (2009) 1.06
Regulation of adult hematopoietic stem cells fate for enhanced tissue-specific repair. Mol Ther (2009) 1.05
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05
Alpha Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol (2003) 1.05
Pathogenesis of simian immunodeficiency virus-induced alterations in macaque trigeminal ganglia. J Neuropathol Exp Neurol (2007) 1.05
Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles. Clin Diagn Lab Immunol (2002) 1.04
Telestroke in South Carolina. J Stroke Cerebrovasc Dis (2011) 1.01
Acute manganese administration alters dopamine transporter levels in the non-human primate striatum. Neurotoxicology (2005) 1.01
Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles. J Infect Dis (2001) 1.00
Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques. Mol Ther (2002) 1.00
Hemoglobinopathies. Hematology Am Soc Hematol Educ Program (2003) 1.00
Immune-mediated clearance of virus from the central nervous system. Microbes Infect (2003) 1.00
In vitro suppression of human immunodeficiency virus type 1 replication by measles virus. J Virol (2005) 1.00
A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol (2010) 0.99
Dynamic regulation of functionally distinct virus-specific T cells. Proc Natl Acad Sci U S A (2010) 0.99